An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer

An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer

The anaplastic lymphoma kinase (alk) gene on chromosome 2 encodes a receptor tyrosine kinase protein essential for key signaling pathways regulating cell proliferation and differentiation. Mutations in alk have been implicated in multiple cancers, including non-small cell lung cancer (NSCLC) and ana...

Full description

Saved in:
Bibliographic Details
Main Authors: Richard Junior Zapata Dongo, Julio A. Poterico, Diletta Fontana, Luca Mologni, Carla Alvarez-Chacon, Juan Rojas-Armas, Jaeson Calla
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Pharmacology
Subjects:
ALK
binding energy
deleterious
cancer
lorlatinib
molecular docking
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1605314/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1605314/full

Similar Items